Curevac B.V. SEC Filings

GSK plc reports beneficial ownership of 16,591,937 Common Shares of CureVac N.V., representing 74% of the outstanding class based on 225,172,749 shares. These shares are held of record by Glaxo Group Limited (GGL), an indirect wholly-owned subsidiary. GSK acquired the shares through an initial contribution in connection with CureVac's IPO and a later follow-on purchase, with those prior purchases funded from GGL's internal resources.

The filing discloses that GGL entered a Tender and Support Agreement with BioNTech SE under which GGL agreed to tender all its Common Shares into BioNTech's exchange offer, vote for proposals to facilitate the offer, vote against Alternative Acquisition Proposals and, subject to conditions, terminate certain pre-IPO ISA rights in respect of GGL as of the offer's first settlement date.

Ownership update: Germany’s state bank KfW reports beneficial ownership of 112.84 m CureVac (CVAC) common shares—50.1 % of the 225.17 m shares outstanding—of which 29.87 m are held directly and 82.97 m are subject to an existing Shareholders’ Agreement with dievini/Hopp-affiliated entities.

New agreement: On 31 Jul 2025 KfW executed a Tender and Support Agreement with BioNTech SE (“Buyer”). Acting under a federal mandate and fully indemnified by the German government, KfW must (1) tender all of its shares into the Buyer’s forthcoming Exchange Offer detailed in the 12 Jun 2025 Purchase Agreement, (2) vote for transaction-related proposals and against alternatives, (3) observe interim restrictions on share actions, and (4) waive rights of first refusal and, at closing, terminate the Shareholders’, Relationship and related investment agreements.

Implications: The commitment by CureVac’s controlling 50 % shareholder materially increases the likelihood that the Exchange Offer will reach its minimum acceptance threshold and that the subsequent post-offer reorganisation can proceed. No deal price, exchange ratio or timeline changes are disclosed in this amendment.

CureVac filed a Form 6-K reporting the completion of its annual general meeting of shareholders held on June 26, 2025. The filing primarily serves to notify the submission of voting results from the meeting.

Key Points:

• The company submitted final tabulation of shareholder votes from its annual general meeting
• Document was signed by CEO Alexander Zehnder
• Filing includes Exhibit 99.1 containing the detailed voting results
• Company confirms it files annual reports under Form 20-F

The filing is purely administrative in nature, serving as a notice of foreign private issuer. The information provided in this Form 6-K is not deemed "filed" under Section 18 of the Securities Exchange Act and does not carry the associated liabilities or incorporation by reference under the Securities Act of 1933 or Exchange Act.

CureVac N.V. (CVAC) filed a Form 6-K to notify investors that it issued a press release on June 24, 2025 detailing the voting results from its Annual General Meeting of shareholders. No financial performance metrics, strategic transactions, or operational updates were included in the filing. The company also clarified that the information, including Exhibit 99.1 (the press release), is furnished—not filed—and therefore is not subject to Section 18 liabilities of the Exchange Act nor incorporated by reference into other SEC filings.